Option Bulls Rush Gilead Sciences, Inc. (GILD) Amid Broader Biotech Bounce

Gilead Sciences, Inc. (NASDAQ:GILD) is getting a much-needed lift from sector tailwinds

by Alex Eppstein

Published on Sep 20, 2016 at 2:00 PM

Biotech stocks are outperforming today, on the heels of some major M&A headlines within the sector. Among the drugmakers heading higher on sector tailwinds is Gilead Sciences, Inc. (NASDAQ:GILD) -- which is up 3.2% at $81.54, and in the crosshairs of options traders.

Diving right in, GILD call options are changing hands at two times the usual intraday rate. The most active strike is the October 82.50 call, where traders may be buying new out-of-the-money positions, hoping the underlying stock will topple $82.50 by the close on Friday, Oct. 21 -- when the newly front-month options expire. Meanwhile, even shorter-term bulls are buying to open the weekly 9/23 82-strike call, targeting additional end-of-week upside for GILD.

Today's call buying merely echoes the prevailing trend in the stock's options pits. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have bought to open triple the number of calls as puts in the past two weeks. The resultant call/put volume ratio of 3.13 ranks only 12 percentage points from a 12-month peak.

Further underscoring GILD's call-skew is its Schaeffer's put/call open interest ratio (SOIR) of 0.45, with calls more than doubling puts among options expiring in the next three months. Of note, this SOIR rests only 5 percentage points from an annual low.

Now appears to be a great time to purchase premium on short-term Gilead options. The stock's Schaeffer's Volatility Index (SVI) of 21% outstrips only 4% of readings from the prior year. Additionally, GILD's 30-day at-the-money implied volatility of 21.8% rests in the bottom 8% of all readings from the last 12 months.

Obviously, today's sharp upside move is stoking good vibes in the options pits. However, from a longer-term perspective, Gilead Sciences, Inc. (NASDAQ:GILD) has been nothing short of a technical trainwreck. Year-over-year, the shares have shed almost 23% of their value, and continue to face pressure at their descending 20-week moving average -- located just overhead, at $82.26.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.